High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl.
SARS virus
Viral epidemiology
Viral infection
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
03
2021
accepted:
06
05
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
ppublish
Résumé
In early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe. Between April 21 The seroprevalence was 42.4% (95% confidence interval (CI) 39.8-44.7). Individuals under 18 showed a significantly lower seroprevalence of 27.1% (95% CI 21.3-33.6) than adults (45%; 95% CI 42.2-47.7; OR of 0.455, 95% CI 0.356-0.682, Ischgl was hit early and hard by SARS-CoV-2 leading to a high local seroprevalence of 42.4%, which was lower in individuals below the age of 18 than in adults. Mathematical modeling suggests that a drastic decline of newly infected individuals in Ischgl by the end of April occurred due to the dual impact from the non-pharmacological interventions and a high immunization of the Ischgl population.
Sections du résumé
BACKGROUND
BACKGROUND
In early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe.
METHODS
METHODS
Between April 21
RESULTS
RESULTS
The seroprevalence was 42.4% (95% confidence interval (CI) 39.8-44.7). Individuals under 18 showed a significantly lower seroprevalence of 27.1% (95% CI 21.3-33.6) than adults (45%; 95% CI 42.2-47.7; OR of 0.455, 95% CI 0.356-0.682,
CONCLUSIONS
CONCLUSIONS
Ischgl was hit early and hard by SARS-CoV-2 leading to a high local seroprevalence of 42.4%, which was lower in individuals below the age of 18 than in adults. Mathematical modeling suggests that a drastic decline of newly infected individuals in Ischgl by the end of April occurred due to the dual impact from the non-pharmacological interventions and a high immunization of the Ischgl population.
Identifiants
pubmed: 34870284
doi: 10.1038/s43856-021-00007-1
pii: 7
pmc: PMC8633917
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Euro Surveill. 2020 Oct;25(42):
pubmed: 33094713
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115128
pubmed: 32777699
Nature. 2021 Feb;590(7844):146-150
pubmed: 33142304
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
BMC Med. 2021 Jan 28;19(1):32
pubmed: 33504336
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
J Clin Virol. 2020 Jul;128:104451
pubmed: 32454427
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Bull World Health Organ. 2021 Jan 01;99(1):19-33F
pubmed: 33716331
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
Nature. 2020 Aug;584(7821):420-424
pubmed: 32674112
PLoS Comput Biol. 2020 Dec 10;16(12):e1008409
pubmed: 33301457
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252